Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer.

IF 1.8 Q3 ONCOLOGY Radiation Oncology Journal Pub Date : 2021-09-01 Epub Date: 2021-09-09 DOI:10.3857/roj.2021.00486

Seok-Joo Chun, Jin Ho Kim, Ja Hyeon Ku, Cheol Kwak, Eun Sik Lee, Suzy Kim

{"title":"Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer.","authors":"Seok-Joo Chun, Jin Ho Kim, Ja Hyeon Ku, Cheol Kwak, Eun Sik Lee, Suzy Kim","doi":"10.3857/roj.2021.00486","DOIUrl":null,"url":null,"abstract":"Purpose: We evaluated clinical outcomes of high-risk prostate cancer patients receiving external beam radiotherapy (EBRT) or radical prostatectomy (RP).Materials and methods: Patients were classified as high-risk prostate cancer and received definitive treatment between 2005 and 2015. Patients with previous pelvic radiotherapy, positive lymph node or distant metastasis were excluded. The primary outcomes were prostate cancer-specific survival (PCSS) and distant metastasis-free survival (DMFS).Results: Of 583 patients met the inclusion criteria (77 EBRT and 506 RP). The estimated 10-year PCSS was 97.0% in the RP and 95.9% in the EBRT (p = 0.770). No significant difference was seen in the DMFS (p = 0.540), whereas there was a trend in favor of RP over EBRT in overall survival (OS) (p = 0.068). Propensity score matching analysis with confounding variables was done, with 183 patients (66 EBRT and 117 RP) were included. No significant difference in DMFS, PCSS or OS was found.Conclusion: Our data demonstrated similar oncologic PCSS, OS, and DMFS outcomes between EBRT and RP patients.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/eb/roj-2021-00486.PMC8497867.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3857/roj.2021.00486","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Purpose: We evaluated clinical outcomes of high-risk prostate cancer patients receiving external beam radiotherapy (EBRT) or radical prostatectomy (RP).

Materials and methods: Patients were classified as high-risk prostate cancer and received definitive treatment between 2005 and 2015. Patients with previous pelvic radiotherapy, positive lymph node or distant metastasis were excluded. The primary outcomes were prostate cancer-specific survival (PCSS) and distant metastasis-free survival (DMFS).

Results: Of 583 patients met the inclusion criteria (77 EBRT and 506 RP). The estimated 10-year PCSS was 97.0% in the RP and 95.9% in the EBRT (p = 0.770). No significant difference was seen in the DMFS (p = 0.540), whereas there was a trend in favor of RP over EBRT in overall survival (OS) (p = 0.068). Propensity score matching analysis with confounding variables was done, with 183 patients (66 EBRT and 117 RP) were included. No significant difference in DMFS, PCSS or OS was found.

Conclusion: Our data demonstrated similar oncologic PCSS, OS, and DMFS outcomes between EBRT and RP patients.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

前列腺根治术与外束放疗治疗高危前列腺癌的比较。

目的:评价高危前列腺癌患者接受外束放疗(EBRT)或根治性前列腺切除术(RP)的临床效果。材料与方法:患者被分类为高危前列腺癌，于2005 - 2015年间接受明确治疗。排除既往盆腔放疗、淋巴结阳性或远处转移的患者。主要结局是前列腺癌特异性生存(PCSS)和远端无转移生存(DMFS)。结果:583例患者符合纳入标准(EBRT 77例，RP 506例)。RP组的10年PCSS估计为97.0%，EBRT组为95.9% (p = 0.770)。DMFS无显著差异(p = 0.540)，而RP在总生存期(OS)上优于EBRT (p = 0.068)。对183例患者(EBRT 66例，RP 117例)进行混杂变量倾向评分匹配分析。DMFS、PCSS、OS无显著性差异。结论:我们的数据显示EBRT和RP患者的肿瘤PCSS、OS和DMFS结果相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Radiation Oncology Journal ONCOLOGY-

CiteScore

3.50

自引率

4.30%

发文量